NanoBio® to Present Clinical Data on its Nanoemulsion Adjuvanted Intranasal Flu Vaccine and Novel Anti-Acne Treatment

NanoBio® to Present Clinical Data on its Nanoemulsion Adjuvanted Intranasal Flu Vaccine and Novel Anti-Acne Treatment at ICAAC 2010

ANN ARBOR, Mich., (September 10, 2010) - NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15. The presentation details are as follows:

Poster Presentation G1-197, #206 - "Phase I Study of a Nanoemulsion Adjuvanted Nasal Influenza Vaccine Demonstrates Both Mucosal and Systemic Immune Responses in Humans"

Date: Sunday, Sept. 12 at 11:30 a.m. ET

During the presentation, NanoBio will share clinical data demonstrating that its nanoemulsion adjuvanted intranasal flu vaccine, NB-1008:

  • Elicited both mucosal and systemic immunity following a single intranasal vaccination;
  • Was safe and well tolerated in healthy adults when administered intranasally;

Demonstrated proof-of-concept for needle-free vaccines with increased disease protection that could be valuable for high risk populations.
Poster Presentation L1-1751, #436 - "Evaluation of the Safety and Efficacy of a Novel Anti-Acne Nanoemulsion (NB-003) in a Randomized, Open-Label, Parallel-Group, Single Center Study"

Date: Tuesday, Sept. 14 at 11:15 a.m. ET

During the presentation, NanoBio will share clinical data demonstrating that its topical bactericidal oil-in-water emulsion, NB-003:

  • Demonstrated in vivo reduction of P. acnes, comparable to what has been reported separately for topical antibiotics marketed for the treatment of acne;
  • Was safe and well tolerated in adult subjects when administered topically.

About NanoBio
NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStatTM technology platform. The company's lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.